Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia flag Australia · Delayed Price · Currency is AUD
7.50
-0.09 (-1.19%)
Nov 17, 2026, 11:29 AM AEDT

Clinuvel Pharmaceuticals Earnings Call Transcripts

Fiscal Year 2026

  • AGM 2026

    Ten profitable years and a strong cash position support continued pipeline investment, including vitiligo, NEURACTHEL, and long-acting formulations. U.S. relocation and listing options remain under review, while shareholders pressed for clearer timelines and communication.

  • Delivered a 10th consecutive year of profit, with revenue surpassing AUD 100 million and strong margins. Announced plans to delist from ASX and list on Nasdaq, focusing on U.S. growth and expanding R&D in vitiligo and peptide platforms. Cash reserves rose to AUD 252 million.

  • Revenue grew 4% year-over-year to a record high, with profitability maintained despite a 22% rise in expenses driven by R&D and expansion. Cash reserves reached AUD 233 million, supporting self-funded growth and upcoming catalysts like clinical trial readouts and Nasdaq listing.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021